Stock IMUX IMMUNIC, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Immunic, Inc.

Equities

IMUX

US4525EP1011

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-21 pm EDT 		5-day change 1st Jan Change
1.27 USD -1.55% Intraday chart for Immunic, Inc. -0.78% -15.33%
May. 08 Transcript : Immunic, Inc., Q1 2024 Earnings Call, May 08, 2024
May. 08 Immunic, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Immunic CMO discusses role of clinical trials in biotech development for Clinical Trials Day
AQ
Immunic chief medical officer discusses promising treatments to mark World IBD Day
AQ
Immunic highlights IMU-856 gastrointestinal candidate to mark International Celiac Day
AQ
Immunic CEO Dr Daniel Vitt discusses key Q1 advances and upcoming milestones
AQ
Immunic : Q1 2024 News Release
PU
Immunic: Q1 Earnings Snapshot
AQ
Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update
PR
Immunic to Participate in Investor and Scientific Conferences in May
PR
Immunic Phase 2 EMPhASIS trial data highlighted in peer-reviewed neurology journal
AQ
Immunic Announces Publication of Extended Data from Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology Neuroimmunology and Neuroinflammation
AQ
Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update
PR
Immunic CEO Dr Daniel Vitt marks International Day of Immunology with discussion on its crucial role
AQ
Immunic to Host MS R&D Day and Participate in Investor Conferences in April
PR
Immunic CMO discusses complexities of multiple sclerosis to mark MS Awareness Month
AQ
Immunic secures key patent, boosting MS drug exclusivity and global IP strategy
AQ
Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States
PR
Immunic to reveal promising MS treatment data in two poster presentations at ACTRIMS Forum 2024
AQ
Immunic to Participate in Investor and Scientific Conferences in March
PR
Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024
PR
Immunic reports successful 2023 and prepares for key 2025 milestones
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IMUX Stock
  4. News Immunic, Inc.
  5. Press Releases
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW